Abstract 14636: The Effect of Enhanced External Counter Pulsation in Blood Lipid Profile in Patients With Coronary Artery Disease
Introduction: Enhanced External Counter pulsation is a non invasive treatment option for patients with coronary artery disease. The treatment works by stimulating the exercise training effect in peripheral vascular and coronary vascular bed and thereby enhancing systemic endothelial function and myocardial angiogenesis by sheer stress.
Hypothesis: EECP effects in cardio vascular systems are very similar to moderate to intense cardiac rehabilitation program. We assessed the effects of EECP in blood lipid profile in patient with coronary artery who are refractory to medical management with poor exercise tolerance.
Methods: We investigate the effect of EECP in lipid profile in 66 consecutive patients who have taken EECP. All the patients’ pre and post Lipid profile was measured in the same lab within 2 weeks of starting and completion of 35 one hour session of EECP treatment. Patient’s drug including statin was not changed and no special diet or exercise was prescribed during the course of treatment.
Results: Patient mean age of 56 yrs and 85% of them are male. All of them are on statin and no change in dosage is done during the treatment. Demography includes 77% has hypertension , 17% Diabetes mellitus, 11% Chronic Renal failure, 54% Triple Vessel Disease. Total cholesterol decreased from baseline 158.37 ± 35.13 to 136 ± 28.55,( p<.0001) Triglyceride decrease from 141.11 ± 74.12 to 109.72 ± 39.86,( p<.0001) LDL decrease from 90.40 ± 28.71 to 75.54 ± 24.03, ( p<.0001) VLDL decrease from 26.65 ± 9.90 to 21.29 ± 7.98( p<.0001)and HDL increase from 39.14 ± 3.67 to 42.35 ± 3.47.( p<.0001)
Conclusions: Complete course of 35 sessions of EECP has shown to have a positive effect on lipid profile. The level of improvement is greater than what we can achieve through aerobic exercise program. Further randomised study is needed to confirm this finding and to see whether this effect is sustained after stopping EECP therapy.
Author Disclosures: R. Subramanian: None. H. Padh: None. S. N: None. P.G. Nayar: None.
- © 2016 by American Heart Association, Inc.